Female patients with debilitating, life-changing symptoms that are dismissed by male doctors as simply 'just hormones'.

A neuroscientist, he employed a battery of high-tech tools in devising a fast-acting therapy that targets the area of the ...

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...

Millions of Americans with anxiety and depression struggle to find the right medication. The best fit may depend on your ...

Research on adults who take S.S.R.I.s shows they tamp down sexual desire. Why aren’t we studying what that could mean for ...

Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, ...

The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar ...

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.

To fight the dark, the answer is to provide more light where it is missing. The standard treatment for SAD is bright-light therapy with a light box that delivers at least 10,000 lux of light.

Analysts suspected that the mid-stage trial miss wouldn't ding Neurocrine’s share price since expectations around the program were "near-zero." ...